Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Dr. Glenn Simon Tillotson worked over 35 years in healthcare with almost 30 years in pharmaceuticals (R&D and Medical Affairs). He has completed his Bachelor of Science in Microbiology and Biochemistry from Liverpool Polytechnic, Liverpool, UK (1974-1978). In 1980 he received his Master of Science in Medicine from University of Manchester Medical School, Manchester, UK. Dr. Glenn Simon Tillotson was Visiting Distinguished Scientist of Public Health Research Institute in NYC (2001). In 2005, he has finished his Ph D from Richmond University, London. He worked as Fellow of Royal Society of Medicine, London, UK (2000), American College of Chest Physicians, Chicago (2006), International Society of Chemotherapy (2008) and Infectious Disease Society of America (2010). He received Alfred Soffer Award by American College of Chest Physicians for Editorial Excellence. Dr. Glenn Simon Tillotson has experience in drug research and development including pre-clinical studies, IND, NDA, MAA and product life cycle extension (sNDA). He had memberships of various societies. In 2014 and 2015, he worked as Scientific Advisory Board- Spero Pharmaceuticals, Cambridge MA and Scientific Advisory Board- Assembly BioSciences, NYC, respectively. Currently, Dr. Glenn Simon Tillotson working as Senior Vice President of Medical Affairs in Cempra Pharmaceuticals, Chapel Hill. He has demonstrated success in range of product development, product launches and life cycle management strategies, harnessed innovative communication strategies both externally and internally, developed several medical affairs teams both internationally and nationally and shown resourcefulness in business development activities. He served as Editorial Board and Reviewer for 24 different journals from 1991 to 2014). He has written 200 papers (>150 papers on PubMed), 5 book chapters. He edited e-book on Clostridium difficile, published in September 2013 by Future Medicine, London, UK. ï Given >500 lectures to National, Regional or State conferences.
Glenn S Tillotson has over 30 years pharmaceutical experience in pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management and global launch programs. He has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin, fidaxomicin and several other agents. He is a SVP of Medical Affairs where he is preparing for the launch of solithromycin for community acquired bacterial pneumonia.
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals